Literature DB >> 28129475

Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study.

J Antonio Aviña-Zubieta1, Fergus To2, Kateryna Vostretsova2, Mary De Vera1, Eric C Sayre1, John M Esdaile1.   

Abstract

OBJECTIVE: To estimate the future risk and time trends of newly diagnosed myocardial infarction (MI), ischemic stroke, or both (cardiovascular disease [CVD]) in individuals with systemic lupus erythematosus (SLE).
METHODS: Using a population-based database that includes all residents of British Columbia, Canada, we conducted a matched cohort study of all patients with incident SLE and up to 10 age-, sex-, and entry time-matched individuals from the general population. We compared incidence rates (IRs) of MI, ischemic stroke, or CVD (i.e., MI or ischemic stroke) between the 2 groups according to SLE disease duration. We calculated hazard ratios (HRs), adjusting for confounders.
RESULTS: Among 4,863 individuals with SLE (86% female, mean age 48.9 years), the IRs of MI, stroke, and CVD were 6.4, 4.4, and 9.9 events per 1,000 person-years, respectively, versus 2.8, 2.3, and 4.7 events per 1,000 person-years in the comparison cohort. Compared with non-SLE individuals, the fully adjusted multivariable HRs among SLE patients were 2.61 (95% confidence interval [95% CI] 2.12-3.20) for MI, 2.14 (95% CI 1.64-2.79) for stroke, and 2.28 (95% CI 1.90-2.73) for CVD. The age-, sex-, and entry time-matched HRs for MI, stroke, and CVD were highest during the first year after SLE diagnosis: 5.63 (95% CI 4.02-7.87), 6.47 (95% CI 4.42-9.47), and 6.28 (95% CI 4.83-8.17), respectively.
CONCLUSION: Patients with SLE have an increased risk of cardiovascular events, particularly during the first year after diagnosis. Increased vigilance in monitoring for these potentially fatal outcomes and their modifiable risk factors is recommended in this patient population.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28129475     DOI: 10.1002/acr.23018

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  29 in total

1.  Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis.

Authors:  Patompong Ungprasert; Eric L Matteson; Cynthia S Crowson
Journal:  Am J Cardiol       Date:  2017-06-15       Impact factor: 2.778

2.  Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).

Authors:  April M Jorge; Na Lu; Yuqing Zhang; Sharan K Rai; Hyon K Choi
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

3.  The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases.

Authors:  April M Jorge; Na Lu; Sarah F Keller; Sharan K Rai; Yuqing Zhang; Hyon K Choi
Journal:  J Rheumatol       Date:  2018-09-01       Impact factor: 4.666

4.  Baseline Elevations of Leukotriene Metabolites and Altered Plasmalogens Are Prognostic Biomarkers of Plaque Progression in Systemic Lupus Erythematosus.

Authors:  Sahar Baig; Kamala Vanarsa; Huihua Ding; Anto Sam Crosslee Louis Sam Titus; Maureen McMahon; Chandra Mohan
Journal:  Front Cardiovasc Med       Date:  2022-05-16

5.  Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.

Authors:  Svetlana Krasnokutsky; Aaron Garza Romero; Daisy Bang; Virginia C Pike; Binita Shah; Talia F Igel; Irina Dektiarev; Yu Guo; Judy Zhong; Stuart D Katz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

6.  Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus.

Authors:  Sarah K Chen; Medha Barbhaiya; Daniel H Solomon; Hongshu Guan; Kazuki Yoshida; Candace H Feldman; Brendan M Everett; Karen H Costenbader
Journal:  J Rheumatol       Date:  2019-11-01       Impact factor: 4.666

7.  Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus.

Authors:  Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Sarah K Chen; Michael A Fischer; Daniel H Solomon; Brendan M Everett; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2018-07-31       Impact factor: 5.532

8.  All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Authors:  Bahar Moghaddam; Shelby Marozoff; Lingyi Li; Eric C Sayre; J Antonio Aviña- Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

9.  Perfusion image guided mechanical thrombectomy combined with tirofiban successfully revascularize systemic lupus erythematosus related acute large vessel occlusion: A case report.

Authors:  Han Wang; Haitao Hu; Jing Xu; Cong Qian
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

10.  Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

Authors:  May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.